Serum Levels of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor-Alpha Are Elevated in Children With Langerhans Cell Histiocytosis

Rosso, Diego; Ripoli, Mario; Roy, Adriana; Díez, Roberto A.; Zelazko, Marta; Braier, Jorge

doi:10.1097/00043426-200306000-00010

Cited by 27 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously reported that pretreatment serum levels of TNF-␣, sIL-2R, and IL-1Ra are elevated in LCH (11,22). Similarly, in the present study, these immunomodulating cytokines were highly expressed in LCH patients at the time of onset of disease; moreover, a significant positive correlation was observed between TNF-␣ and OPG serum concentrations, at the time of diagnosis.…”

supporting

confidence: 85%

“…We have previously shown that pretreatment serum levels of soluble IL-2 receptor (sIL-2R), IL-1 receptor antagonist (IL-1Ra), and TNF-␣ are elevated in children with LCH (11,22). In the present study, we analyzed serum levels of these cytokines in LCH patients at the time of diagnosis [TNF-␣ (n ϭ 9), sIL-2R (n ϭ 12), IL-1Ra (n ϭ 11)] as well as in pediatric controls (n ϭ 14 for TNF-␣ and sIL-2R measurements, and n ϭ 7 for IL-Ra measurements).…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, our recent studies have revealed elevated levels of TNF-␣ in the serum of LCH patients (11), and we have shown the addition of anti-TNF-␣ treatment to conventional chemotherapy to be beneficial in a child with severe LCH (12).…”

mentioning

confidence: 82%

“…The performance range was 62.5-4000 pg/mL and the detection limit was 30 pg/mL. Serum levels of sIL-2R and IL-1Ra were estimated using commercial ELISA kits obtained from R&D Systems, as previously described (11,22). TNF-␣ concentrations were determined by chemiluminescent immunometric assay using an IMMULITE automated analyzer (Diagnostic Products, Los Angeles, CA), according to the manufacturer's instructions.…”

Section: Methodsmentioning

confidence: 99%

“…LCH is associated with high expression of several cytokines, both in serum and in granulomatous lesions in these patients (6,8,11,22,38). We have previously reported that pretreatment serum levels of TNF-␣, sIL-2R, and IL-1Ra are elevated in LCH (11,22).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Elevated Serum Levels of the Decoy Receptor Osteoprotegerin in Children with Langerhans Cell Histiocytosis

et al. 2006

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is characterized by an accumulation of dendritic Langerhans cells in granulomatous lesions in the bone, skin, and other sites in the body. The pathogenesis of the disease remains unknown. We measured serum levels of the decoy receptor osteoprotegerin (OPG), an important regulator of bone metabolism as well as immune responses, in 18 children with single system (SS) or multi-system (MS) forms of LCH and 20 pediatric controls. OPG levels were significantly increased in LCH patients at diagnosis when compared with controls, and pretreatment levels of OPG were elevated in MS compared with SS patients. Moreover, OPG levels in LCH patients were elevated in patients with involvement of risk organs (liver, lungs, hematopoietic system, or spleen) when compared with patients without risk organ involvement, indicative of an association between OPG values and disease severity. We also observed a positive correlation between serum levels of OPG and tumor necrosis factor (TNF)-␣, a proinflammatory cytokine, at the time of onset of disease. These findings show, for the first time, that serum OPG levels are elevated in LCH patients, and suggest that OPG may play a role in the pathogenesis of this enigmatic disease. (Pediatr Res 59: 281-286, 2006)

show abstract

supporting

confidence: 85%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 82%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Elevated Serum Levels of the Decoy Receptor Osteoprotegerin in Children with Langerhans Cell Histiocytosis

et al. 2006

View full text Add to dashboard Cite

show abstract

Cutaneous Infiltrates of Myeloid Derivation

2016

The Cutaneous Lymphoid Proliferations

View full text Add to dashboard Cite

Characteristic of Langerhans cell histiocytosis in oral and maxillofacial regions

Shiiba

Baba

Eizuka

et al. 2020

Oral Science International

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH） is a rare disease caused by excessive proliferation of Langerhans cells in various regions of the body. Previous studies have reported that 10% of LCH occurs in the oral and maxillofacial regions. In the oral and maxillofacial regions, swelling and pain are the typical symptoms, and jaw fracture and tooth loss are often seen in advanced cases. In this study, we present the results of a literature review of LCH that developed in the oral and maxillofacial regions. The history, pathological conditions, diagnosis, treatment, and progress of LCH are discussed.

show abstract

Serum Levels of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor-Alpha Are Elevated in Children With Langerhans Cell Histiocytosis

Abstract: Patients with LCH have elevated levels of IL-1Ra and TNF, which decrease after chemotherapy.

Cited by 27 publications

References 19 publications

Elevated Serum Levels of the Decoy Receptor Osteoprotegerin in Children with Langerhans Cell Histiocytosis

Elevated Serum Levels of the Decoy Receptor Osteoprotegerin in Children with Langerhans Cell Histiocytosis

Cutaneous Infiltrates of Myeloid Derivation

Characteristic of Langerhans cell histiocytosis in oral and maxillofacial regions

Contact Info

Product

Resources

About